Vaccine Access
The financing, pricing, supply, and delivery needed so everyone who needs a vaccine can get one without delay.
Seven Reasons Why The World Needs New TB Vaccines Advocacy Conversation Starters and Key Messages presents seven key messages that can serve as “conversation starters” when advocating for new TB vaccines across a wide variety of stakeholders. The seven messages together provides a unified backbone for all TB vaccine messaging grounded in evidence-based narratives that resonate with decision-makers that can be adapted for local contexts based on the key interests and needs of unique communities.
Governments and donors must be aware of market challenges related to supply, demand, and financing that will threaten equitable access to future TB vaccines. Without thoughtful planning and intervention, the global demand for TB vaccines will exceed supply in the years following launch. Governments, funders, developers, manufacturers, civil society, and other stakeholders must take, starting today, to avert deadly supply shortages tomorrow.
This statement reflects on the proposal to create a “global catalytic instrument” to support future TB vaccines and calls on all stakeholders to learn from the introduction of other tools like long-acting prevention tools for HIV and act early to ensure adequate financing and supply to realize the success of a future TB vaccine.
What Could Go Right? Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, explores the foundational role that community and civil society groups can play in the successful introduction of a new TB vaccine and strategies for capacitating and empowering communities towards that goal. In bringing together three unique sub-studies, this first-of-its-kind report examines community and civil society’s readiness to engage in TB vaccine advocacy and policymaking at national, regional, and global levels, and underscores the transformative role communities can play in TB vaccine introduction, as well as the critical need for other stakeholders to help them realize that potential.
Communities and civil society organizations are poised to play an indispensable role in ensuring the success of new TB vaccines by building the “infrastructures of trust” that are foundational to vaccine acceptance, demand, and equitable access.
What Could Go Right: Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines explores the indispensable role of communities and civil society in preparing the way for new TB vaccines and ensuring their success once they become available. The report brings together three unique studies that assess the readiness of community and civil society to contribute to TB vaccine policymaking and implementation at national, regional, and global levels, and the investments funders should make to strengthen community capacity and engagement.
- No Vaccines Without Us: A Global Landscape Analysis of Civil Society Engagement in TB Vaccine Preparedness is based on a global survey of 125 civil society organizations active in the TB response in 42 countries and documents the readiness of CSOs to participate in new TB vaccine policymaking, demand creation, and implementation.
- Seven Country Policy Portraits, written by local activists, illustrate how vaccine policy is made in seven countries — Bangladesh, Kazakhstan, Kenya, Malawi, Mongolia, South Africa, and Vietnam — and propose reforms to strengthen the representation of community partners in national immunization decision making.
- TB Vaccine Access in “4D”: A Roadmap Charting Civil Society Actions for Equitable Access outlines a series of actions civil society can take with the support of other key stakeholders to assure access to new TB vaccines along four dimensions: development, delivery, demand, and data.
The World Health Organization’s Evidence Considerations for Vaccine Policy Development (ECVP) focuses on TB vaccines intended for adults and adolescents and is designed to support the product development, regulatory approval, introduction, access and widespread use in LMICs of new TB vaccines. The ECVP does not pre-empt policy or implementation decision-making but aims to reduce the risk of evidence gaps and consequent delays between vaccine regulatory approval and vaccine impact.
Early this decade, the WHO commissioned a study into the rationale for investing in new TB vaccines from the country perspective. This case study provides early evidence for policy and decision-makers to assess the grounds for investing in TB vaccines, vaccine research, financing, manufacturing, introduction, and procurement. Early and regular investments from key stakeholders supports the acceleration of the development of new, effective TB vaccines and their potential introduction.
The World Health Organization‘s Catalyzing solutions for equitable global access and sustainable financing for novel tuberculosis vaccines for adults and adolescents report assesses country readiness, demand and supply projections, product development pathways and the global financing landscape to understand potential uncertainties and bottlenecks affecting early introduction, including demand fragmentation, manufacturing capacity constraints, regulatory dependencies and financing gaps in potential TB vaccine introduction over the 2030–2040 period. The report also offers a set of solutions and mechanisms designed to proactively address these foreseen challenges.
From Forest to Factory: Tracing the Supply Chains for Two Modern Adjuvants of Global Health Importance — QS-21 and MPL provides a first-of-its-kind analysis of the global supply chains of two key adjuvants used in several of the world’s most important vaccines. The report paints a detailed picture of QS-21 supply drawing on information from newly public data on QS-21. The report provides recommendations on how supply chains for adjuvants can be strengthened through greater transparency, competition, and sustainability with the goal of maximizing the global health impact of adjuvant development for equitable access to vaccines.
The WHO framework to prepare for Country Introduction of New TB Vaccines for Adults and Adolescents was designed to support the planning, investments, and preparation for the rapid introduction and scale-up of TB vaccines for adults and adolescents so that they are available such that new vaccines are manufactured with sufficient, sustainable and timely supply; accessible, with equitable delivery aimed at all who could benefit and accepted, so that end-users, healthcare workers, and policy makers´ requirements are met.



